Literature DB >> 10624910

Effect of erythromycin on myocardial repolarization in patients with community-acquired pneumonia.

A Kdesh1, C A McPherson, Y Yaylali, D Yasick, K Bradley, C A Manthous.   

Abstract

BACKGROUND: Erythromycin has been associated with prolongation of myocardial repolarization and torsades de pointes (TdP).
METHODS: To determine the frequency, dose-response, and risk factors for erythromycin-associated prolongation of myocardial repolarization, we observed data of patients admitted to our hospital with pneumonia who were treated with erythromycin.
RESULTS: In 35 women and 28 men enrolled in this study, the QTc increased from 434 +/- 4 milliseconds at baseline to 464 +/- 5 milliseconds after receiving a cumulative dose of 3.2 +/- 0.2 g of erythromycin. Neither age, sex, presence of preexistent congestive heart failure/coronary artery disease, electrolyte values, nor cumulative dose of erythromycin was associated with QTc prolongation. In 27 patients who received intravenous erythromycin for 3 days, the QTc increased from 427 +/- 5 milliseconds before to 461 +/- 8 milliseconds at 24 hours but did not increase further by day 3 (457 +/- 10 milliseconds). No patient in this cohort had TdP.
CONCLUSIONS: Erythromycin therapy is associated with prolongation of myocardial repolarization that manifests after the first few doses in a majority of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10624910     DOI: 10.1097/00007611-199912000-00009

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

Review 1.  Macrolide antibiotics and the risk of cardiac arrhythmias.

Authors:  Richard K Albert; Joseph L Schuller
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

Review 2.  Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2016
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.